INN 73rd Executive Summary
73rd Consultation on International Nonproprietary Names
Overview
Two new stems/substems were selected, 5 suffixes were promoted to the pre-stem list and it was decided to review the descriptions of 5 stems/pre-stems.
A new scheme for Monoclonal Antibody (mAbs) Nomenclature has been accepted by INN Expert Group.
mAbs have been divide into four groups, with suffixes as follows:
• Group 1 comprises mAbs that are mono-specific and unmodified. Previously it was proposed that they would retain the -mab stem; however, given that other types of mAbs would have novel suffixes, it was felt best to drop the -mab stem altogether to avoid any confusion or misunderstanding. An alternative suffix -tug or -cab for mono-specific and unmodified mAbs was proposed.
• Group 2 comprises mono-specific, full length mAbs that have an engineered constant domain, and would be named with a -bart suffix, for ‘antibody artificial’.
• Group 3 comprises bi- or multi-specific mAbs, regardless of their format, type or shape, and the suffix -mig, for multispecific-immunoglobulin was proposed, as before.
• Group 4 comprises mAbs that are monospecific fragments of any kind, and that are derived from an immunoglobulin variable domain, and the suffix -ment for fragment was proposed.